Collegium Pharmaceutical, Inc. $COLL Shares Purchased by Janus Henderson Group PLC

Posted by on Aug 2nd, 2026

Janus Henderson Group PLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 26.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,825,651 shares of the specialty pharmaceutical company’s stock after acquiring an additional 377,073 shares during the period. Janus Henderson Group PLC owned about 0.06% of Collegium Pharmaceutical worth $60,358,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Vident Advisory LLC lifted its position in shares of Collegium Pharmaceutical by 1.9% in the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after purchasing an additional 281 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock worth $324,000 after purchasing an additional 282 shares during the last quarter. Atom Investors LP raised its stake in Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock valued at $284,000 after purchasing an additional 294 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of Collegium Pharmaceutical by 9.3% during the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 335 shares during the period.

Collegium Pharmaceutical Trading Down 1.6%

Collegium Pharmaceutical stock opened at $35.39 on Friday. The firm has a 50-day moving average of $34.84 and a 200-day moving average of $37.55. Collegium Pharmaceutical, Inc. has a one year low of $29.19 and a one year high of $50.79. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 17.35 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same period last year, the company earned $1.49 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. On average, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent analyst reports. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Check Out Our Latest Analysis on COLL

Collegium Pharmaceutical Company Profile

(Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Featured Stories

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.